Xencor, Verastem ink new deals; Scynexis' lead drug scores again
→ Xencor has inked a deal with Gilead Sciences. Gilead will have access to Xencor’s Xtend extended half-life and Cytotoxic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
